摘要
目的探讨富血小板纤维蛋白在骨缺损愈合中的作用,为临床应用提供参考。方法在健康雄性山羊的下颌骨制备3个直径6 mm、厚2 mm圆形骨缺损,前2个缺损放置富血小板纤维蛋白(实验组)、口腔修复膜(修复膜组),最后一组不放置填充物(空白组)。分别在术后4、8及12周制取标本,行组织学观察和骨形态计量学分析,比较三组的成骨效果。结果镜下观察显示,术后4、8、12周实验组和修复膜组缺损区成骨效果均好于空白组,成骨细胞活跃,骨小梁粗而排列有序;空白组成骨效果较差,骨小梁较细,纤维成分较多。骨计量学结果显示,在术后4、8和12周,实验组和修复膜组的骨小梁面积百分比均高于空白组,差异有统计学意义(P<0.05);而实验组和修复膜组的骨小梁面积百分比比较,差异无统计学意义(P>0.05)。结论在实验性骨缺损中,富血小板纤维蛋白有促进成骨作用。
Objective To explore the effect of the platelet-rich fibrin in the healing of bone defects,to provide reference for clinical application.Methods Three round bone defects(diameter 6 mm,thickness 2 mm)were made on the mandible of healthy male goats.Platelet-rich fibrin(experimental group)and oral repair membrane(repair membrane group)were filled in the first two defects,and the final defect was empty(blank group).The specimens were made at 4,8 and 12 weeks after operation for microscopy observation and osteometric analysis,and the osteogenic effect was compared in the three groups.Results There were many orderly arranged osteoblasts and trabeculaes in the experimental group and repair membrane group while there were fewer trabeculaes and more fibers in the blank group under microscopy at 4,8 and 12 weeks after operation,which indicated that the experimental group and repair membrane group had better osteogenic effect than the blank group.Osteometric analysis showed that at 4,8 and 12 weeks after operation,the percentage of trabecular area in the experimental group and the repair membrane group was higher than that in the blank group,the difference was statistically significant(P<0.05).But there was no significant difference in the percentage of trabecular area between the experimental group and the repair membrane group(P>0.05).Conclusion Platelet-rich fibrin can promote osteogenesis in experimental bone defects.
作者
戴勇中
严国安
叶平
刘阳
DAI Yong-zhong;YAN Guo-an;YE Ping;LIU Yang(Department of Stomatology,Yingtan Hospital of Traditional Chinese Medicine,Jiangxi Province,Yingtan335000,China;Jiangxi Taikang Baibo Dental Hospital,Jiangxi Province,Nanchang330000,China)
出处
《中国当代医药》
CAS
2021年第6期13-16,F0004,共5页
China Modern Medicine
基金
江西省鹰潭市科技计划项目(YKZ20180072)。
